Drug shortages

Oxaliplatin Injection

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

To Be Discontinued25021-233-20Oncology
Open FDA's page for this record
Discontinued date
06/29/2026
Update type
New
Initial posting date
06/29/2026
Package NDC
25021-233-20
Generic name
Oxaliplatin Injection
Contact info
Sagent Pharmaceuticals: 866-625-1618
Related info
Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug
Update date
06/29/2026
Dosage form
Injection
Presentation
Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20)
Company name
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Status
To Be Discontinued
Therapeutic category
Oncology
Harmonized identifiers (openFDA)
Application number
ANDA203869
Brand name
OXALIPLATIN
Generic name
OXALIPLATIN
Manufacturer name
Sagent Pharmaceuticals
Product NDC
25021-233
Product type
HUMAN PRESCRIPTION DRUG
Route
INTRAVENOUS
Substance name
OXALIPLATIN
RxCUI
1736776, 1736781
SPL ID
c159050a-e588-4091-b9ee-ea502e1b9529
SPL set ID
29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f
Package NDC
25021-233-10, 25021-233-20
Nui
N0000175413, N0000175073
Pharm class epc
Platinum-based Drug [EPC]
UNII
04ZR38536J
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.